CLINICAL TRIALS PROFILE FOR EXPAREL
✉ Email this page to a colleague
505(b)(2) Clinical Trials for EXPAREL
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT01349140 ↗ | EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks | Completed | Pacira Pharmaceuticals, Inc | Phase 1 | 2012-02-01 | EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve. |
| New Formulation | NCT01349140 ↗ | EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks | Completed | University of California, San Diego | Phase 1 | 2012-02-01 | EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for EXPAREL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00485433 ↗ | Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair | Completed | Pacira Pharmaceuticals, Inc | Phase 2 | 2007-06-01 | The purpose of this study is to evaluate three dose levels of SKY0402 compared with 105 mg of bupivacaine HCl. |
| NCT00485693 ↗ | Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty | Completed | Pacira Pharmaceuticals, Inc | Phase 2 | 2007-06-01 | Dose-ranging study for prolonged postoperative analgesia in subjects undergoing total knee arthroplasty |
| NCT00529126 ↗ | Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy | Completed | Pacira Pharmaceuticals, Inc | Phase 2 | 2007-09-01 | Phase 2 study to evaluate three dose levels of SKY0402 compared with 75 mg of bupivacaine HCl. |
| NCT00813111 ↗ | Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation | Terminated | Pacira Pharmaceuticals, Inc | Phase 3 | 2008-11-01 | The purpose of this study is to provide a more effective postoperative method of pain control for patients undergoing cosmetic sub-muscular breast augmentation. Appropriate postoperative pain management contributes to faster patient mobilization, shortened hospital stays, and reduced healthcare costs. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EXPAREL
Condition Name
Clinical Trial Locations for EXPAREL
Trials by Country
Clinical Trial Progress for EXPAREL
Clinical Trial Phase
Clinical Trial Sponsors for EXPAREL
Sponsor Name
